BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 15361497)

  • 1. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study.
    Bassi A; Dodd S; Williamson P; Bodger K
    Gut; 2004 Oct; 53(10):1471-8. PubMed ID: 15361497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn's & Colitis Foundation.
    Park KT; Ehrlich OG; Allen JI; Meadows P; Szigethy EM; Henrichsen K; Kim SC; Lawton RC; Murphy SM; Regueiro M; Rubin DT; Engel-Nitz NM; Heller CA
    Inflamm Bowel Dis; 2020 Jan; 26(1):1-10. PubMed ID: 31112238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs of inflammatory bowel disease in Germany.
    Stark R; König HH; Leidl R
    Pharmacoeconomics; 2006; 24(8):797-814. PubMed ID: 16898849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-of-illness of inflammatory bowel disease patients treated with anti-tumour necrosis factor: A French large single-centre experience.
    Lawton J; Achit H; Pouillon L; Boschetti E; Demore B; Matton T; Tournier C; Prodel M; Peyrin-Biroulet L; Guillemin F
    United European Gastroenterol J; 2019 Aug; 7(7):908-913. PubMed ID: 31428415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic Burden and Health Care Access for Patients With Inflammatory Bowel Diseases in China: Web-Based Survey Study.
    Yu Q; Zhu C; Feng S; Xu L; Hu S; Chen H; Chen H; Yao S; Wang X; Chen Y
    J Med Internet Res; 2021 Jan; 23(1):e20629. PubMed ID: 33399540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Impact of Inflammatory Bowel Disease in Canada 2018: Indirect Costs of IBD Care.
    Kuenzig ME; Lee L; El-Matary W; Weizman AV; Benchimol EI; Kaplan GG; Nguyen GC; Bernstein CN; Bitton A; Lee K; Cooke-Lauder J; Murthy SK
    J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S34-S41. PubMed ID: 31294383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mental Health Costs of Inflammatory Bowel Diseases.
    Szigethy E; Murphy SM; Ehrlich OG; Engel-Nitz NM; Heller CA; Henrichsen K; Lawton R; Meadows P; Allen JI
    Inflamm Bowel Dis; 2021 Jan; 27(1):40-48. PubMed ID: 32095835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct health-care cost utilization in Hong Kong inflammatory bowel disease patients in the initial 2 years following diagnosis.
    Mak LY; Ng SC; Wong IOL; Li MKK; Lo FH; Wong MTL; Leung CM; Tsang SWC; Chan KH; Sze SF; Shan EHS; Lam BCY; Hui AJ; Hung IFN; Leung WK
    J Gastroenterol Hepatol; 2018 Jan; 33(1):141-149. PubMed ID: 28475813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.
    Kuenzig ME; Benchimol EI; Lee L; Targownik LE; Singh H; Kaplan GG; Bernstein CN; Bitton A; Nguyen GC; Lee K; Cooke-Lauder J; Murthy SK
    J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S17-S33. PubMed ID: 31294382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost of illness analysis of inflammatory bowel disease.
    Pakdin M; Zarei L; Bagheri Lankarani K; Ghahramani S
    BMC Gastroenterol; 2023 Jan; 23(1):21. PubMed ID: 36658489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The excess cost of acute exacerbations of chronic bronchitis in patients aged 45 and older in England and Wales.
    McGuire A; Irwin DE; Fenn P; Gray A; Anderson P; Lovering A; MacGowan A
    Value Health; 2001; 4(5):370-5. PubMed ID: 11705127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study.
    Burisch J; Vardi H; Schwartz D; Friger M; Kiudelis G; Kupčinskas J; Fumery M; Gower-Rousseau C; Lakatos L; Lakatos PL; D'Incà R; Sartini A; Valpiani D; Giannotta M; Arebi N; Duricova D; Bortlik M; Chetcuti Zammit S; Ellul P; Pedersen N; Kjeldsen J; Midjord JMM; Nielsen KR; Winther Andersen K; Andersen V; Katsanos KH; Christodoulou DK; Domislovic V; Krznaric Z; Sebastian S; Oksanen P; Collin P; Barros L; Magro F; Salupere R; Kievit HAL; Goldis A; Kaimakliotis IP; Dahlerup JF; Eriksson C; Halfvarson J; Fernandez A; Hernandez V; Turcan S; Belousova E; Langholz E; Munkholm P; Odes S;
    Lancet Gastroenterol Hepatol; 2020 May; 5(5):454-464. PubMed ID: 32061322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital.
    Bernstein CN; Papineau N; Zajaczkowski J; Rawsthorne P; Okrusko G; Blanchard JF
    Am J Gastroenterol; 2000 Mar; 95(3):677-83. PubMed ID: 10710056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.
    Buxton M; Caine N; Chase D; Connelly D; Grace A; Jackson C; Parkes J; Sharples L
    Health Technol Assess; 2006 Aug; 10(27):iii-iv, ix-xi, 1-164. PubMed ID: 16904046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost of outpatient care in patients with inflammatory bowel disease in a German University Hospital.
    Ebinger M; Leidl R; Thomas S; Von Tirpitz C; Reinshagen M; Adler G; Konig HH
    J Gastroenterol Hepatol; 2004 Feb; 19(2):192-9. PubMed ID: 14731130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determinants of Healthcare Utilization Among Veterans with Inflammatory Bowel Disease.
    Tan MC; El-Serag HB; Hou JK
    Dig Dis Sci; 2017 Mar; 62(3):607-614. PubMed ID: 28012103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phenome-Wide Analysis of Healthcare Costs Associated with Inflammatory Bowel Diseases.
    Cai W; Cagan A; He Z; Ananthakrishnan AN
    Dig Dis Sci; 2021 Mar; 66(3):760-767. PubMed ID: 32436120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health Care Cost Analysis in a Population-based Inception Cohort of Inflammatory Bowel Disease Patients in the First Year of Diagnosis.
    Niewiadomski O; Studd C; Hair C; Wilson J; McNeill J; Knight R; Prewett E; Dabkowski P; Dowling D; Alexander S; Allen B; Tacey M; Connell W; Desmond P; Bell S
    J Crohns Colitis; 2015 Nov; 9(11):988-96. PubMed ID: 26129692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study.
    van der Valk ME; Mangen MJ; Leenders M; Dijkstra G; van Bodegraven AA; Fidder HH; de Jong DJ; Pierik M; van der Woude CJ; Romberg-Camps MJ; Clemens CH; Jansen JM; Mahmmod N; van de Meeberg PC; van der Meulen-de Jong AE; Ponsioen CY; Bolwerk CJ; Vermeijden JR; Siersema PD; van Oijen MG; Oldenburg B;
    Gut; 2014 Jan; 63(1):72-9. PubMed ID: 23135759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of Safety, Medical Resource Utilization, and Treatment Costs by Drug Class for Management of Inflammatory Bowel Disease in the United States Based on Insurance Claims Data.
    Long GH; Tatro AR; Oh YS; Reddy SR; Ananthakrishnan AN
    Adv Ther; 2019 Nov; 36(11):3079-3095. PubMed ID: 31562607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.